RE: Manipulation9 Jun 2021 14:50
Can’t trust the reported trades as gospel. Much of what is reported is smoke and mirrors. No manipulation but a worked order or a false spread, like now, if the true reported spread was represented, this would be blue.
AGL is a platform, so I couldn’t consider it as a one trick pony as it has worked for every cancer type tested. It also works for Protien/DNA/RNA, so again plenty of strings to its bow. FDA for breast followed by Ovarian cancer assay which provides two major inflection points this year alone. You could also argue with the labs that it now has a service and a product, especially upon Clia lab validation.
It’s true to say that with volume particularly low, and signs of supply of stock curtailing as investors reposition or look for new opportunities elsewhere following an approx 240% rise, we have continued to see new buyers taking their place with a higher average investment. But with a £280m market cap (only), it’s all up for grabs now the foundations are in place. We have seen this healthy consolidation at 80 and now in the 120/30’s. I have watched people come and go and the underlying tone change to suit their book, but they will be back again.
I am certain that the market cap doesn’t adequately price in an FDA outcome and that in combination with further pharma contracts, by the time that decision comes we will be a lot higher.
With a De Novo label creating barriers to entry, in addition to the multiple IP’s in place, any first mover advantage that will see multiple partnerships with majors upon approval will be enough to see this dual list on the Nasdaq with a valuation of over a billion dollars.
I see little point in chasing rainbows when our research and performance to date in a challenging market emphasizes that we are already onto a winner.
Sign In
Follow the stocks
